Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

IIR 16-078 – HSR Study

IIR 16-078
Effectiveness of a Rescue Medication in Preventing Opioid Overdose in Veterans
Elizabeth Marie Oliva, PhD
VA Palo Alto Health Care System, Palo Alto, CA
Palo Alto, CA
Funding Period: December 2018 - December 2023


Background: In Spring 2014 the VA launched a national Opioid Overdose Education and Naloxone Distribution (OEND) program with the support of the VA Under Secretary for Health1. In launching VA's OEND initiative, the Under Secretary for Health acknowledged that most of the evidence to date surrounds OEND targeting community-dwelling persons with documented opioid use disorders or opioid misuse rather than all patients receiving opioid analgesics in a health care system. The VA OEND program was the first to target two distinct patient populations: (1) patients with opioid use disorders and (2) patients prescribed opioid analgesics. As of May 22, 2016 VA facilities have dispensed just over 27,000 naloxone kits to Veterans with every VA facility participating in naloxone distribution (VA Naloxone Kit Distribution Report). As the first large health care system in the United States to implement OEND, there is a great deal that can be learned from VA in terms of whether current recommendations for OEND implementation are sound and/or whether they should be tailored to specific subsets of patients. To address concerns about the effectiveness of OEND in health care settings, an evaluation of OEND is necessary to examine whether it reduces opioid overdose as intended for at-risk patients prescribed opioid analgesics and patients with opioid use disorders. Objectives: The proposed study will pursue the following objectives: Objective 1: Characterize naloxone distribution within VA and patient-, prescriber-, and setting-related factors associated with distribution. Objective 2: Assess whether naloxone distribution to at-risk Veterans compared to similar at-risk Veterans who did not receive naloxone is associated with reduced fatal and non-fatal opioid overdose. Theoretical Framework: The Reach, Effectiveness, Adoption, Implementation, and Maintenance—RE-AIM— framework will guide our study. This framework considers both individual- (e.g., patient) and institutional-level (e.g., setting) factors when evaluating the impact of interventions. Methods: We will identify a cohort of patients from Fiscal Year 2014 Quarter 3 (FY2014 Q3; the start of the national OEND program) through FY2017 Q1 (end of calendar year 2016) comprising at-risk patient populations: (1) patients with opioid use disorders and (2) at-risk patients prescribed opioid analgesics. Objective 1: For the identified cohort, we will obtain data from the VA Corporate Data Warehouse (CDW) and provide descriptive statistics on the characteristics of patients who receive naloxone, prescribers who prescribe naloxone, and settings in which naloxone is prescribed. We will also use mixed-effects logistic regression models to identify patient-, prescriber-, and setting-level differences between patients who do and do not receive naloxone. Objective 2: Our primary analysis will use marginal structural models (MSMs) to examine the effect of naloxone distribution for two main sets of outcomes: (1) Fatal opioid overdose—unintentional, intentional, and combined and (2) Non-fatal opioid overdose—unintentional, intentional, and combined. MSMs are a method for controlling for selection bias by using inverse probability of treatment weights which follow many of the same principles as propensity score analysis. Uncommon observations (persons who get the unexpected treatment) get greater weight, and common observations get less weight. All at-risk patients will be included in our analyses and we will obtain fatal overdose outcomes from the VA/Department of Defense (DoD) National Death Index and non-fatal overdose outcomes from CDW. Summary: The VA is leading the nation with regards to health care system-based implementation of naloxone distribution. The proposed study will characterize implementation of this innovative program and assess whether naloxone distribution is meeting its intended goal of reducing opioid overdose among at-risk Veterans.

External Links for this Project

NIH Reporter

Grant Number: I01HX002193-01A1

Dimensions for VA

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

Learn more about Dimensions for VA.

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.
    Search Dimensions for this project


Journal Articles

  1. Bounthavong M, Harvey MA, Kay CL, Lau MK, Wells DL, Himstreet JE, Popish SJ, Oliva EM, Christopher MLD. Comparison of naloxone prescribing patterns due to educational outreach conducted by full-time and part-time academic detailers at the U.S. Veterans Health Administration. Journal of the American Pharmacists Association : JAPhA. 2020 Jul 1; 60(4):639-646. [view]
  2. Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, Oliva EM, Goldhaber-Fiebert JD, Asch SM, Brandeau ML, Owens DK. Cost-effectiveness of Treatments for Opioid Use Disorder. JAMA psychiatry. 2021 Jul 1; 78(7):767-777. [view]
  3. Joyce VR, Oliva EM, Garcia CC, Trafton J, Asch SM, Wagner TH, Humphreys K, Owens DK, Bounthavong M. Healthcare costs and use before and after opioid overdose in Veterans Health Administration patients with opioid use disorder. Addiction (Abingdon, England). 2023 Nov 1; 118(11):2203-2214. [view]

DRA: Substance Use Disorders
DRE: Prevention, TRL - Applied/Translational, Treatment - Observational
Keywords: Pharmacology, Substance Use and Abuse
MeSH Terms: None at this time.

Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.